Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than expected operating costs. Cresemba (for invasive mould infections), in particular, continues to pick up momentum both in the EU and the US through US partner Astellas. Zevtera’s US pivotal Phase III clinical trial programme for bacterial infections remains on track to initiate in mid-2017. Multiple distribution and commercialisation agreements sig
01 Mar 2017
Steady as she goes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Steady as she goes
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
01 Mar 2017 -
Author:
Dr Susie Jana -
Pages:
7
Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than expected operating costs. Cresemba (for invasive mould infections), in particular, continues to pick up momentum both in the EU and the US through US partner Astellas. Zevtera’s US pivotal Phase III clinical trial programme for bacterial infections remains on track to initiate in mid-2017. Multiple distribution and commercialisation agreements sig